Ustekinumab, a monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23, has demonstrated efficacy in reducing GM-CSF+ Th cell numbers and alleviating β cell loss in T1D models 108. Here, CSF2 is linked to type 1 diabetes mellitus.